Andreas Halvorsen‘s hedge fund agency Viking Global has filed a 13G with the SEC relating to shares of aTyr Pharma (LIFE). Per the submitting, Viking now owns % of the corporate with over 2.93 million shares.
This is a newly disclosed fairness place and the submitting was made because of exercise on August 31st. aTyr Pharma lately issued a press launch stating that they’d raised $45 million in fairness financing, with Viking buying a block of non-voting Class X Preferred Stock at $13.25 per share, every which converts into 5 shares of widespread inventory with numerous circumstances.
We’ve highlighted earlier portfolio activity from Viking Global here.
Per Google Finance, aTyr Pharma is “a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.”
SOURCE: market folly – Read whole story here.